Skip to main content
OpenTrials
Completed

NCT Number: NCT04759040

Improvement of Migraine Severity and Frequency With Migraineguard ™

Numerous treatments have been recommended for the prevention of migraine. The purpose of this randomized double-blind placebo controlled trial was to assess the efficacy of MIGRAINEGUARD ™ supplement by Herbacure Natural containing a combination of COQ10 , magnesium, riboflavin ,feverfew , Skullcap and black pepper as prophylactic treatment for migraine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Migraine Brain Diseases Central Nervous System Diseases Headache Headache Disorders Headache Disorders, Primary Migraine Disorders Nervous System Diseases Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Herbacure Natural

Burnaby, British Columbia, V3J 1N3, Canada

About this study

Our team will assess MIGRAINEGUARD ™ , a migraine prevention supplement marketed Herbacure Natural for individual suffering from multiple migraine attacks in one month . The purpose of this 7-months , randomized, double-blind, placebo controlled study is to evaluate the efficacy and safety of MIGRAINEGUARD ™ produced by Herbacure Natural , A Canadian company based in Vancouver , BC , in reducing migraine headache severity and frequency of attacks compared to placebo when used every day, as a preventative solution for migraine and to assess and monitor the safety of its usage for adverse effects.

The primary end-point is the severity and the frequency reduction of migraine attacks. The secondary end-points will be the existence of adverse reaction.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult aged 18 to 65 years Female and Male
  • Based on IHS criteria ,are diagnosed with migraine (criteria of the International Classification of Headaches Disorders)
  • Individuals with minimum of 3 severe to extreme migraine attacks during the last 3 months .
  • Generally in good health

Exclusion criteria

  • Individuals taking any preventive treatment for migraine
  • Excessive usage of painkillers
  • Cancer & Head injury and trauma
  • Any medical condition that may impact the validity of collected information
  • Previous usage of Botox within 6 months of study
  • Last week usage of triptans

Treatment and study plan

Migraineguard

Dietary Supplement

2 Capsules per day for 7 Months

Primary outcomes

  1. Number of patient experiencing migraine attack reduction by at least 50 percent in one month .

    Time frame: 7 months

    Number of patient experiencing migraine attack reduction by at least 50 percent in one month . Migraineurs with 50 percent migraine attack decrease are considered "Responders" to supplement.

  2. Severity of migraine headache reduction after & Months

    Time frame: 7 Months

    Reduction of Migraine severity After 7 months of supplementation

Secondary outcomes

  1. Adverse Reactions

    Time frame: 7 months

    Report of any adverse reaction due to supplementation during the study

Sponsors and collaborators

Lead sponsor

Herbacure Natural

Industry

Registry information

Official study title

Migraineguard ™ Supplement Reduces the Severity and Frequency of Migraine , a Randomized, Placebo-controlled, Double-blind, Trial

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Feb 17, 2021
Registry last updated
Mar 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.